Unravelling The Complexities of Cervical Cancer: A Comprehensive Exploration
Oncology-Cervical cancer
DOI:
https://doi.org/10.22376/ijtos.2024.2.2.23-31Keywords:
Cervical cancer, Epidemiology, Human papillomavirus, Treatments, VaccinesAbstract
Cervical cancer (CC) ranks as the second most common cause of cancer-related deaths among women aged 20-39, resulting in ten premature deaths weekly. CC affects women worldwide as the most common form of genital cancer, with approximately 500,000 new cases diagnosed annually. Besides the risk of death, CC can lead to increased morbidity, causing symptoms like pain, haemorrhage, and kidney failure. These complications pose significant challenges to treatment, particularly in areas with limited healthcare access. Immune dysregulation and chronic inflammation further contribute to CC pathogenesis, creating a pro-carcinogenic microenvironment through immune cell recruitment, cytokine release, and inflammatory responses triggered by persistent HPV infection. Moreover, understanding the socio-economic determinants influencing the prevalence of CC and promoting awareness can contribute to effective public health interventions. Research endeavours in these domains are vital to reduce the burden of CC, enhance early detection, and ultimately save lives. This review covers recent research on CC global epidemiology, intricate pathogenesis insights, protein-based HPV vaccines, and diverse treatment modalities, including recurrent cases. Molecular markers indicating prognosis and the role of artificial intelligence. The review will briefly highlight preventive strategies, offering a comprehensive overview of crucial research areas in CC.
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2021 May;71(3):209-49.
Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, Bray F. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. The Lancet Global Health. 2020 Feb 1;8(2):e191-203.
Hull R, Mbele M, Makhafola T, Hicks C, Wang SM, Reis RM, Mehrotra R, Mkhize Kwitshana Z, Kibiki G, Bates DO, Dlamini Z. Cervical cancer in low and middle-income countries. Oncology letters. 2020 Sep 1;20(3):2058-74.
Zur Hausen H. Papillomaviruses in the causation of human cancers- a brief historical account. Virology. 2009 Feb 20;384(2):260-5.
Torre LA, Islami F, Siegel RL, Ward EM, Jemal A. Global cancer in women: burden and trends. Cancer epidemiology, biomarkers & prevention. 2017 Apr 1;26(4):444-57.
Chrysostomou AC, Stylianou DC, Constantinidou A, Kostrikis LG. Cervical cancer screening programs in Europe: the transition towards HPV vaccination and population-based HPV testing. Viruses. 2018 Dec 19;10(12):729.
Zahnd WE, Murphy C, Knoll M, Benavidez GA, Day KR, Ranganathan R, Luke P, Zgodic A, Shi K, Merrell MA, Crouch EL. The intersection of rural residence and minority race/ethnicity in cancer disparities in the United States. International journal of environmental research and public health. 2021 Feb;18(4):1384.
Poondla N, Madduru D, Duppala SK, Velpula S, Nunia V, Kharb S, Ghatak S, Mishra AK, Vuree S, Neyaz MK, Suravajhala P. Cervical cancer in the era of precision medicine: A perspective from developing countries. Advances in Cancer Biology-Metastasis. 2021 Dec 1;3:100015.
Loiseau V, Peccoud J, Bouzar C, Guillier S, Fan J, Gueli Alletti G, Meignin C, Herniou EA, Federici BA, Wennmann JT, Jehle JA. Monitoring insect transposable elements in large double-stranded DNA viruses reveals host-to-virus and virus-to-virus transposition. Molecular biology and evolution. 2021 Sep 1;38(9):3512-30.
Matsuo K, Nusbaum DJ, Machida H, Huang Y, Khetan V, Matsuzaki S, Klar M, Grubbs BH, Roman LD, Wright JD. Populational trends and outcomes of postoperative radiotherapy for high-risk early-stage cervical cancer with lymph node metastasis: concurrent chemo-radiotherapy versus radiotherapy alone. American journal of obstetrics and gynecology. 2020 May 1;222(5):484-e1.
Wright JD, Matsuo K, Huang Y, Tergas AI, Hou JY, Khoury-Collado F, Clair CM, Ananth CV, Neugut AI, Hershman DL. Prognostic performance of the 2018 International Federation of Gynecology and Obstetrics cervical cancer staging guidelines. Obstetrics and gynecology. 2019 Jul;134(1):49.
Lambaudie E, de Nonneville A, Brun C, Laplane C, N’Guyen Duong L, Boher JM, Jauffret C, Blache G, Knight S, Cini E, Houvenaeghel G. Enhanced recovery after surgery program in Gynaecologic Oncological surgery in a minimally invasive techniques expert center. BMC surgery. 2017 Dec;17:1-9.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International journal of cancer. 2015 Mar 1;136(5):E359-86.
Patel K, Foster NR, Kumar A, Grudem M, Longenbach S, Bakkum-Gamez J, Haddock M, Dowdy S, Jatoi A. Hydronephrosis in patients with cervical cancer: an assessment of morbidity and survival. Supportive Care in Cancer. 2015 May;23:1303-9.
Sathishkumar K, Sankarapillai J, Mathew A, Nair RA, Gangane N, Khuraijam S, Barmon D, Pandya S, Majumdar G, Deshmane V, Zomawia E. Survival of patients with cervical cancer in India–findings from 11 population based cancer registries under National Cancer Registry Programme. The Lancet Regional Health-Southeast Asia. 2023 Oct 13.
Park KJ, Roma AA. Pattern-based classification of endocervical adenocarcinoma: a review. Pathology. 2018 Feb 1;50(2):134-40.
Yim EK, Park JS. The role of HPV E6 and E7 oncoproteins in HPV-associated cervical carcinogenesis. Cancer research and treatment: official journal of Korean Cancer Association. 2005 Dec 31;37(6):319-24.
Joseph J, Mary H, Sudarsanam D. Insilico Modelling Of The Integrative Pathway Of Carcinoma By Hpv E6 Protein–Protein Interaction. International Journal of Pharma and Bioscience. 2014;5(1):1107-1.
Sasagawa T, Takagi H, Makinoda S. Immune responses against human papillomavirus (HPV) infection and evasion of host defense in cervical cancer. Journal of Infection and Chemotherapy. 2012 Jan 1;18(6):807-15.
Zhang B, Li P, Wang E, Brahmi Z, Dunn KW, Blum JS, Roman A. The E5 protein of human papillomavirus type 16 perturbs MHC class II antigen maturation in human foreskin keratinocytes treated with interferon-γ. Virology. 2003 May 25;310(1):100-8.
Wikipedia Contributors. Cervical cancer [Internet]. Wikipedia. Wikimedia Foundation; 2019. Available from: https://en.wikipedia.org/wiki/Cervical_cancer
Peng S, Ferrall L, Gaillard S, Wang C, Chi WY, Huang CH, Roden RB, Wu TC, Chang YN, Hung CF. Development of DNA vaccine targeting E6 and E7 proteins of human papillomavirus 16 (HPV16) and HPV18 for immunotherapy in combination with recombinant vaccinia boost and PD-1 antibody. MBio. 2021 Feb 23;12(1):10-128.
Skeate JG, Woodham AW, Einstein MH, Da Silva DM, Kast WM. Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases. Human vaccines & immunotherapeutics. 2016 Jun 2;12(6):1418-29.
Eldredge-Hindy HB, Eastwick G, Anne PR, Rosenblum NG, Schilder RJ, Chalian R, Zibelli AM, Kim CH, Den R. Adjuvant vaginal cuff brachytherapy for high-risk, early stage endometrial cancer. Journal of Contemporary Brachytherapy. 2014 Jul 1;6(3):262-70.
Stewart AJ, Viswanathan AN. Current controversies in high‐dose‐rate versus low‐dose‐rate brachytherapy for cervical cancer. Cancer: Interdisciplinary International Journal of the American Cancer Society. 2006 Sep 1;107(5):908-15.
van de Bunt L, Van der Heide UA, Ketelaars M, de Kort GA, Jürgenliemk-Schulz IM. Conventional, conformal, and intensity-modulated radiation therapy treatment planning of external beam radiotherapy for cervical cancer: The impact of tumor regression. International Journal of Radiation Oncology* Biology* Physics. 2006 Jan 1;64(1):189-96.
Mettler L, Schollmeyer T, Tinelli A, Malvasi A, Alkatout I. Complications of uterine fibroids and their management, surgical management of fibroids, laparoscopy and hysteroscopy versus hysterectomy, haemorrhage, adhesions, and complications. Obstetrics and Gynecology International. 2012 Apr 9;2012.
Kim MK, Kim MA, Kim JW, Chung HH, Park NH, Yong-Sang S, Kang SB. Loop electrosurgical excision procedure findings for identification of patients with early-stage cervical cancer suitable for less radical surgery. International Journal of Gynecological Cancer. 2012 Sep 1;22(7):1214-9.
He M, Wang Y, Zhang G, Cao K, Yang M, Liu H. The prognostic significance of tumor-infiltrating lymphocytes in cervical cancer. Journal of Gynecologic Oncology. 2021 May;32(3).
Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nature reviews cancer. 2012 Apr;12(4):237-51.
Nicholas S, Chen L, Choflet A, Fader A, Guss Z, Hazell S, Song DY, Tran PT, Viswanathan AN. Pelvic radiation and normal tissue toxicity. InSeminars in radiation oncology 2017 Oct 1 (Vol. 27, No. 4, pp. 358-369). WB Saunders.
Zhang N, Tang Y, Guo X, Mao Z, Yang W, Cheng G. Analysis of dose-effect relationship between DVH parameters and clinical prognosis of definitive radio (chemo) therapy combined with intracavitary/interstitial brachytherapy in patients with locally advanced cervical cancer: A single-center retrospective study. Brachytherapy. 2020 Mar 1;19(2):194-200.
Franco P, Arcadipane F, Ragona R, Mistrangelo M, Cassoni P, Munoz F, Rondi N, Morino M, Racca P, Ricardi U. Volumetric modulated arc therapy (VMAT) in the combined modality treatment of anal cancer patients. The British Journal of Radiology. 2016 Apr;89(1060):20150832.
Kollmeier MA, Gorovets D, Flynn J, McBride S, Brennan V, Beaudry J, Cohen G, Damato A, Zhang Z, Zelefsky MJ. Combined brachytherapy and ultra-hypofractionated radiotherapy for intermediate-risk prostate cancer: Comparison of toxicity outcomes using a high-dose-rate (HDR) versus low-dose-rate (LDR) brachytherapy boost. Brachytherapy. 2022 Sep 1;21(5):599-604.
Orang’o E, Itsura P, Tonui P, Muliro H, Rosen B, van Lonkhuijzen L. Use of palliative cisplatinum for advanced cervical cancer in a resource-poor setting: a case series from Kenya. Journal of Global Oncology. 2017 Oct;3(5):539-44.
Gershenson DM, Miller AM, Champion VL, Monahan PO, Zhao Q, Cella D, Williams SD. Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group Study. Journal of Clinical Oncology. 2007 Jul 1;25(19):2792-7.
Li C, Shintani S, Terakado N, Klosek SK, Ishikawa T, Nakashiro K, Hamakawa H. Microvessel density and expression of vascular endothelial growth factor, basic fibroblast growth factor, and platelet-derived endothelial growth factor in oral squamous cell carcinomas. International journal of oral and maxillofacial surgery. 2005 Jul 1;34(5):559-65.
D’Souza A, Roman LD, Saura C, Braña I, Shapiro GI, Passalacqua R, Piha-Paul S, Cutler RE, Shahin S, Eli LD, Xu F. Neratinib in patients with HER2-mutant, metastatic cervical cancer: findings from the phase 2 SUMMIT ‘basket’trial. Gynecologic oncology. 2019 Jun 1;154:11.
Rabenau K, Hofstatter E. DNA damage repair and the emerging role of poly (ADP-ribose) polymerase inhibition in cancer therapeutics. Clinical therapeutics. 2016 Jul 1;38(7):1577-88.
Basu P, Mehta A, Jain M, Gupta S, Nagarkar RV, John S, Petit R. A randomized phase 2 study of ADXS11-001 Listeria monocytogenes–Listeriolysin O immunotherapy with or without cisplatin in treatment of advanced cervical cancer. International journal of gynecological cancer. 2018 May;28(4):764.
Rossetti D, Vitale SG, Tropea A, Biondi A, Laganà AS. New procedures for the identification of sentinel lymph node: shaping the horizon of future management in early stage uterine cervical cancer. Updates in Surgery. 2017 Sep;69:383-8.
Tewari KS, Sill MW, Monk BJ, Penson RT, Moore DH, Lankes HA, Ramondetta LM, Landrum LM, Randall LM, Oaknin A, Leitao MM. Circulating tumor cells in advanced cervical cancer: NRG oncology-gynecologic oncology group study 240 (NCT 00803062). Molecular cancer therapeutics. 2020 Nov 1;19(11):2363-70.
Wentzensen N, von Knebel Doeberitz M. Biomarkers in cervical cancer screening. Disease markers. 2007 Jan 1;23(4):315-30.
Hemavathy V, Julius A. A study to assess the quality of life among women with cervical cancer in selected hospitals at Chennai. International Journal of Pharma and Bio Sciences. 2016 Oct 17;7(4).b722-724.
Wang AC, Wang LQ, Li J, Li MX, Tu LL, Zhang YX, Liu AJ. Artificial intelligence aided measurement of cervical squamous epithelial thickness and its correlation with cervical precancerous lesions. Zhonghua bing li xue za zhi= Chinese journal of pathology. 2021 Apr 1;50(4):339-43.
Sarwar A, Sheikh AA, Manhas J, Sharma V. Segmentation of cervical cells for automated screening of cervical cancer: a review. Artificial Intelligence Review. 2020 Apr;53:2341-79.
Holcakova J, Bartosik M, Anton M, Minar L, Hausnerova J, Bednarikova M, Weinberger V, Hrstka R. New trends in the detection of gynecological precancerous lesions and early-stage cancers. Cancers. 2021 Dec 17;13(24):6339.
Denny L. Cervical cancer: prevention and treatment. Discovery medicine. 2012 Aug 27;14(75):125-31.
Subramanian NS, Patel DR, Mahalakshmi B, Ganvanthbhai RD, Gopal R. Prevention of Cervical Cancer Among Women Aged 25-40 Years in Gujarat.(2023). Int. J. Life Sci. Pharma Res.;13(2):L140-5.
Sehgal A, Singh V. Human papillomavirus infection (HPV) & screening strategies for cervical cancer. Indian Journal of Medical Research. 2009 Sep 1;130(3):234-40.
Riibe MØ, Sørbye SW, Simonsen GS, Sundsfjord A, Ekgren J, Maltau JM. Risk of cervical intraepithelial neoplasia grade 3 or higher (CIN3+) among women with HPV-test in 1990–1992, a 30-year follow-up study. Infectious Agents and Cancer. 2021 Dec;16(1):1-9.
Denny L, Sankaranarayanan R. Secondary prevention of cervical cancer. International Journal of Gynecology & Obstetrics. 2006 Nov 1;94:S65-70.
Canfell K. Towards the global elimination of cervical cancer. Papillomavirus research. 2019 Dec 1;8:100170.
Ghosh S, Seth S, Paul J, Rahman R, Chattopadhyay S, Bhadra D. Evaluation of Pap smear, high risk HPV DNA testing in detection of cervical neoplasia with colposcopy guided or conventional biopsy as gold standard. Int J Healthcare Biomed Res. 2014 Jan;2(2):192-7.
Look M, Bandyopadhyay A, Blum JS, Fahmy TM. Application of nanotechnologies for improved immune response against infectious diseases in the developing world. Advanced drug delivery reviews. 2010 Mar 18;62(4-5):378-93.
Tjalma WA, Arbyn M, Paavonen J, Van Waes TR, Bogers JJ. Prophylactic human papillomavirus vaccines: the beginning of the end of cervical cancer. International Journal of Gynecological Cancer. 2004 Sep;14(5):751-61.
Yuan Y, Cai X, Shen F, Ma F. HPV post-infection microenvironment and cervical cancer. Cancer Letters. 2021 Jan 28;497:243-54.a
Villa LL. Prophylactic HPV vaccines: reducing the burden of HPV-related diseases. Vaccine. 2006 Mar 30;24:S23-8.
Published
How to Cite
Issue
Section
Copyright (c) 2024 Dr. Shilpa Bhargava, Dr. John Abraham, Dr. Martha Srinivas, Dr. Somenath Ghosh
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
